EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH

View source ↗

Summary

EMA authorised Acvybra (denosumab) for osteoporosis-related indications in Europe, with Reddy Holding GmbH as MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Acvybra (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Reddy Holding GmbH. Decision date: 13/07/2026